American Oncology Network highlights phase 3 DLLEVATE trial of ZL-1310 in relapsed small cell lung cancer at ASCO 2026

American Oncology Network, Inc. - Class A Common Stock

AONC

0.00

American Oncology Network flagged multiple research studies selected for presentation at the ASCO 2026 Annual Meeting, May 29–June 2 in Chicago.
Findings will be presented in the future; no trial readouts or study results were disclosed in the announcement.
Pipeline includes a phase 3 study in relapsed small cell lung cancer, a phase 2 study in relapsed or refractory diffuse large B-cell lymphoma.
Additional work focuses on real-world evidence, health equity in guidelines or trials, and AI tools to support community-based research execution.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. American Oncology Network Inc. published the original content used to generate this news brief on May 27, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.